National Cancer Institute's 2018 Director's Award Recognizes Westat Researchers
Westat received the National Cancer Institute’s (NCI’s) Director's Award for Clinical Science on November 8, 2018. The honor spotlights Westat researchers’ work with the National Clinical Trial Network (NCTN) Navigator Clinical Trials Specimen Resource. NCI notes Westat’s work “for outstanding achievement in making a valuable new resource available to the scientific community.”
The award is for the Cancer Trials Support Unit (CTSU) team’s contributions to developing the NCTN Navigator application. The team includes NCI staff and Caroline Porter, Kasi Perumal, Mark Stauffer, and Ravi Rajaram from Westat.
NCTN Navigator receives biospecimen data from 5 different biospecimen banks across the country that handle the specimens for clinical trials led by the 6 NCTNs.
NCTN Navigator can be used by any potential investigator to submit a request to NCI for a specimen for correlative analysis. The investigators can query the NCTN Navigator’s biospecimen repository by different attributes, such as patient’s primary disease, specimen type, or patient demographics.
Learn more about Westat and how we are helping NCI’s CTSU.